HealthcareServices

Cancer In Vitro Diagnostics (IVD) Market Trends and Insights: Global Forecast to 2030

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer in vitro diagnostics (ivd) market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Cancer In Vitro Diagnostics (IVD) Market in 2030?

The market size for cancer in vitro diagnostics (ivd) has shown significant growth recently. It is forecast to increase from $14.32 billion in 2025 to $15.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The expansion observed in previous periods is attributable to factors such as the development of hospital diagnostic infrastructure, an increase in biomarker-based testing, the integration of PCR and immunoassay technologies, the establishment of more cancer screening programs, and enhancements in laboratory automation.

The cancer in vitro diagnostics (ivd) market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $19.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. This growth trajectory during the forecast period is primarily driven by factors such as the increasing need for personalized oncology diagnostics, greater investments in genomic sequencing, the broadening scope of point-of-care cancer testing, the expanding adoption of cloud-based diagnostic platforms, and a heightened emphasis on precision medicine. Key developments expected during this timeframe encompass the wider acceptance of molecular and genomic cancer testing, the escalating application of companion diagnostics, the increasing incorporation of AI-driven data analysis, the broadening utility of liquid biopsy applications, and an intensified commitment to early cancer detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp

What Drivers Are Influencing Production Trends In The Cancer In Vitro Diagnostics (IVD) Market?

The rising occurrence of cancer is projected to drive the expansion of the cancer in vitro diagnostics (IVD) market in the future. Cancer is characterized by the uncontrolled multiplication and dispersion of irregular cells within the body, capable of infiltrating adjacent tissues and forming growths. This increase in cancer cases stems from an aging demographic; extended lifespans and lower death rates from infectious diseases lead to a greater number of older individuals who face an elevated risk of developing the disease. Cancer in vitro diagnostics (IVD) plays a crucial role in combating cancer by facilitating its early and precise detection, continuous monitoring, and effective management. This is achieved via laboratory analyses of patient samples, enabling prompt treatment choices and enhancing patient survival and well-being. As an illustration, in January 2023, the American Cancer Society, a professional body in the US focused on eradicating cancer, disclosed projections for 1,958,310 new cancer cases and 609,820 cancer deaths in 2023 in the United States. Consequently, the growing prevalence of cancer is propelling the development of the cancer in vitro diagnostics (IVD) market.

Which Segments Are Gaining Traction In The Cancer In Vitro Diagnostics (IVD) Market?

The cancer in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Reagents And Kits, Instruments, Software And Services

2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology

3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer

4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users

Subsegments:

1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others

2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others

3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

How Are Emerging Trends Affecting The Progression Of The Cancer In Vitro Diagnostics (IVD) Market?

Leading firms within the cancer in vitro diagnostics market are concentrating their efforts on advancements in cancer screening methods, particularly blood-based colorectal cancer (CRC) screening, with the aim of offering convenient, non-invasive, and precise early detection for colorectal cancer. This type of screening involves identifying molecular changes linked to cancer, like circulating tumor DNA (ctDNA), present in a patient’s blood sample, in order to pinpoint colorectal cancer in individuals at average risk. As an illustration, in July 2024, Guardant Health, Inc., a precision oncology company based in the U.S., secured approval from the U.S. Food and Drug Administration (FDA) for its Guardant Shield blood test, designating it as a primary screening choice for colorectal cancer. The mechanism of this test involves examining a blood sample for particular ctDNA methylation patterns and additional markers derived from tumors. Its distinctive attributes encompass noninvasive sample gathering, exceptional analytical precision, and seamless incorporation into clinical processes for initial screening. Its utility extends to the early identification of colorectal cancer in adults at average risk. Advantages derived from its use include enhanced patient compliance, more timely detection of cancerous conditions, a potential decrease in diagnoses at advanced stages, and qualification for Medicare reimbursement, thereby facilitating wider public access to screening services.

Who Are The Prominent Global Companies Shaping The Cancer In Vitro Diagnostics (IVD) Market Landscape?

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Cancer In Vitro Diagnostics (IVD) Market?

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer In Vitro Diagnostics (IVD) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27234&type=smp

Browse Through More Reports Similar to the Global Cancer In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

Hydraulic Pumps Market Report 2026

https://www.thebusinessresearchcompany.com/report/hydraulic-pumps-global-market-report

Hydraulics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hydraulics-global-market-report

Smart Elevators Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795